Recombinant antibody production leveraging Chinese Hamster Ovary (CHO) cells presents a critical platform for the development of therapeutic monoclonal antibodies. Optimizing this process is essential to achieve high yields and quality antibodies. A variety of strategies can be utilized to optimize